Using in silico modelling and FRET-based assays in the discovery of novel FDA-approved drugs as inhibitors of MERS-CoV helicase

References

• A.M. Zaki, S. Van Boheemen, T.M. Bestebroer, A.D.M.E. Osterhaus, and R.A.M. Fouchier, Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia, N. Engl. J. Med. 367 (2012), pp. 1814–1820. doi:10.1056/NEJMoa1211721.
   PubMed Web of Science ®Google Scholar
• A. Chafekar and B.C. Fielding, MERS-CoV: Understanding the latest human coronavirus threat, Viruses 10 (2018), pp. 93. doi:10.3390/v10020093.
   PubMed Web of Science ®Google Scholar
• A. Mubarak, W. Alturaiki, and M.G. Hemida, Middle East respiratory syndrome coronavirus (MERS-CoV): Infection, immunological response, and vaccine development, J. Immunol. Res. (2019), pp. 6491738. doi:10.1155/2019/6491738.
   PubMed Web of Science ®Google Scholar
• E.I. Azhar, S.A. El-Kafrawy, S.A. Farraj, A.M. Hassan, M.S. Al-Saeed, A.M. Hashem, and T.A. Madani, Evidence for camel-to-human transmission of MERS coronavirus, N. Engl. J. Med. 370 (2014), pp. 2499–2505. doi:10.1056/NEJMoa1401505.
   PubMed Web of Science ®Google Scholar
• V.S. Raj, A.D.M.E. Osterhaus, R.A.M. Fouchier, and B.L. Haagmans, MERS: Emergence of a novel human coronavirus, Curr. Opin. Virol. 5 (2014), pp. 58–62. doi:10.1016/j.coviro.2014.01.010.
   PubMed Web of Science ®Google Scholar
• K.M. Das, E.Y. Lee, S.E. Al Jawder, M.A. Enani, R. Singh, L. Skakni, N. Al-Nakshabandi, K. AlDossari, and S.G. Larsson, Acute Middle East respiratory syndrome coronavirus: Temporal lung changes observed on the chest radiographs of 55 patients, Am. J. Roentgenol. 205 (2015), pp. W267–W274. doi:10.2214/AJR.15.14445.
   PubMed Web of Science ®Google Scholar
• T.M. Lohman, Escherichia coli DNA helicases: Mechanisms of DNA unwinding, Mol. Microbiol. 6 (1992), pp. 5–14. doi:10.1111/j.1365-2958.1992.tb00831.x.
   PubMed Web of Science ®Google Scholar
• T.M. Lohman and K.P. Bjornson, Mechanisms of helicase-catalyzed DNA unwinding, Annu. Rev. Biochem. 65 (1996), pp. 169–214. doi:10.1146/annurev.bi.65.070196.001125.
   PubMed Web of Science ®Google Scholar
• T.M. Lohman, Helicase-catalyzed DNA unwinding, J. Biol. Chem. 268 (1993), pp. 2269–2272.
   PubMed Web of Science ®Google Scholar
• G.W. Owttrim, RNA helicases: Diverse roles in prokaryotic response to abiotic stress, RNA Biol. 10 (2013), pp. 96–110. doi:10.4161/rna.22638.
   PubMed Web of Science ®Google Scholar
• R.M. Brosh and S.W. Matson, History of DNA helicases, Genes (Basel) 11 (2020), pp. 255. doi:10.3390/genes11030255.
   Web of Science ®Google Scholar
• K. Geider and H. Hoffmann-Berling, Proteins controlling the helical structure of DNA, Annu. Rev. Biochem. 50 (1981), pp. 233–260. doi:10.1146/annurev.bi.50.070181.001313.
   PubMed Web of Science ®Google Scholar
• S. Lain, J.L. Riechmann, and J.A. Garciá, RNA helicase: A novel activity associated with a protein encoded by a positive strand RNA virus, Nucleic Acids Res. 18 (1990), pp. 7003–7006. doi:10.1093/nar/18.23.7003.
   PubMed Web of Science ®Google Scholar
• Z. Xing, W.K. Ma, and E.J. Tran, The DDX5/Dbp2 subfamily of DEAD-box RNA helicases, Wiley Interdiscip. Rev. RNA 10 (2019), pp. e1519. doi:10.1002/wrna.1519. 2.
   PubMed Web of Science ®Google Scholar
• V. Khemici and P. Linder, RNA helicases in RNA decay, Biochem. Soc. Trans. 46 (2018), pp. 163–172. doi:10.1042/BST20170052.
   PubMed Web of Science ®Google Scholar
• A.K. Byrd and K.D. Raney, Displacement of a DNA binding protein by Dda helicase, Nucleic Acids Res. 34 (2006), pp. 3020–3029. doi:10.1093/nar/gkl369.
   PubMed Web of Science ®Google Scholar
• C.S. Jordan and S.W. Morrical, Regulation of the bacteriophage T4 Dda helicase by Gp32 single-stranded DNA-binding protein, DNA Repair (Amst.) 25 (2015), pp. 41–53. doi:10.1016/j.dnarep.2014.10.002
   PubMed Web of Science ®Google Scholar
• S. Aarattuthodiyil, A.K. Byrd, and K.D. Raney, Simultaneous binding to the tracking strand, displaced strand and the duplex of a DNA fork enhances unwinding by Dda helicase, Nucleic Acids Res. 42 (2014), pp. 11707–11720. doi:10.1093/nar/gku845.
   PubMed Web of Science ®Google Scholar
• J. Xia, L.T. Chen, Q. Mei, C.H. Ma, J.A. Halliday, H.Y. Lin, D. Magnan, J.P. Pribis, D.M. Fitzgerald, H.M. Hamilton, M. Richters, R.B. Nehring, X. Shen, L. Li, D. Bates, P.J. Hastings, C. Herman, M. Jayaram, and S.M. Rosenberg, Holliday junction trap shows how cells use recombination and a junction-guardian role of RecQ helicase, Sci. Adv. 2 (2016), pp. e1601605. doi:10.1126/sciadv.1601605.
   PubMed Web of Science ®Google Scholar
• B. Bartholomew, ISWI chromatin remodeling: One primary actor or a coordinated effort, Curr. Opin. Struct. Biol. 24 (2014), pp. 150–155. doi:10.1016/j.sbi.2014.01.010.
   PubMed Web of Science ®Google Scholar
• R. Lestini and B. Michel, UvrD controls the access of recombination proteins to blocked replication forks, Embo J. 26 (2007), pp. 3804–3814. doi:10.1038/sj.emboj.7601804.
   PubMed Web of Science ®Google Scholar
• O. Cordin, J. Banroques, N.K. Tanner, and P. Linder, The DEAD-box protein family of RNA helicases, Gene 367 (2006), pp. 17–37. doi:10.1016/j.gene.2005.10.019.
   PubMed Web of Science ®Google Scholar
• A.O. Adedeji and H. Lazarus, Biochemical characterization of Middle East respiratory syndrome coronavirus helicase, mSphere 1 (2016), pp. e00235–16. doi:10.1128/mSphere.00235-16.
   PubMed Web of Science ®Google Scholar
• N. Zhang, S. Jiang, and L. Du, Current advancements and potential strategies in the development of MERS-CoV vaccines, Expert. Rev. Vaccines 6 (2014), pp. 761–774. doi:10.1586/14760584.2014.912134.
   Google Scholar
• M. Alnazawi, A. Altaher, and M. Kandeel, Comparative genomic analysis MERS CoV isolated from humans and camels with special reference to virus encoded helicase, Biol. Pharm. Bull. 40 (2017), pp. 1289–1298. doi:10.1248/bpb.b17-00241
   PubMed Web of Science ®Google Scholar
• V. Thiel, K.A. Iva, Á. Putics, T. Hertzig, B. Schelle, S. Bayer, B. Weißbrich, E.J. Snijder, H. Rabenau, H.W. Doerr, A.E. Gorbalenya, and J. Ziebuhr, Mechanisms and enzymes involved in SARS coronavirus genome expression, J. Gen. Virol. 84 (2003), pp. 2305–2315. doi:10.1099/vir.0.19424-0.
   PubMed Web of Science ®Google Scholar
• L. Subissi, I. Imbert, F. Ferron, A. Collet, B. Coutard, E. Roly, and B. Canard, SARS-CoV ORF1b-encoded nonstructural proteins 12-16: Replicative enzymes as antiviral targets, Antiviral Res. 101 (2014), pp. 122–130. doi:10.1016/j.antiviral.2013.11.006.
   PubMed Web of Science ®Google Scholar
• L. Subissi, C.C. Posthuma, A. Collet, J.C. Zevenhoven-Dobbe, A.E. Gorbalenya, E. Roly, E.J. Snijder, B. Canard, and I. Imbert, One severe acute respiratory syndrome coronavirus protein complex integrates processive RNA polymerase and exonuclease activities, Proc. Natl. Acad. Sci. U S A 111 (2014), pp. E3900–E3909. doi:10.1073/pnas.1323705111.
   PubMed Web of Science ®Google Scholar
• E. Prentice, J. McAuliffe, X. Lu, K. Subbarao, and M.R. Denison, Identification and characterization of severe acute respiratory syndrome coronavirus replicase proteins, J. Virol. 78 (2004), pp. 9977–9986. doi:10.1128/JVI.78.18.9977-9986.2004.
   PubMed Web of Science ®Google Scholar
• K.A. Iva, V. Thiel, J.C. Dobbe, Y. van der Meer, E.J. Snijder, and J. Ziebuhr, Multiple enzymatic activities associated with severe acute respiratory syndrome coronavirus helicase, J. Virol. 78 (2004), pp. 5619–5632. doi:10.1128/JVI.78.11.5619-5632.2004.
   PubMed Web of Science ®Google Scholar
• J.A. Tanner, R.M. Watt, Y.B. Chai, L.Y. Lu, M.C. Lin, J.S. Peiris, L.L. Poon, H.F. Kung, and J.D. Huang, The severe acute respiratory syndrome (SARS) coronavirus NTPas/helicase belongs to a distinct class of 5′ to 3′ viral helicases, J. Biol. Chem. 278 (2003), pp. 39578–39582. doi:10.1074/jbc.C300328200.
   PubMed Web of Science ®Google Scholar
• W. Hao, J.A. Wojdyla, R. Zhao, R. Han, R. Das, I. Zlatev, M. Manoharan, M. Wang, and S. Cui, Crystal structure of Middle East respiratory syndrome coronavirus helicase, PLoS Pathog. 13 (2017), pp. e1006474. doi:10.1371/journal.ppat.1006474.
   PubMed Web of Science ®Google Scholar
• A.O. Adedeji, K. Singh, N.E. Calcaterra, M.L. DeDiego, L. Enjuanes, S. Weiss, and S.G. Sarafianos, Severe acute respiratory syndrome coronavirus replication inhibitor that interferes with the nucleic acid unwinding of the viral helicase, Antimicrob. Agents Chemother. 56 (2012), pp. 4718–4728. doi:10.1128/AAC.00957-12.
   PubMed Web of Science ®Google Scholar
• A.O. Adedeji, K. Singh, A. Kassim, C.M. Coleman, R. Elliott, S.R. Weiss, M.B. Frieman, and S.G. Sarafianos, Evaluation of SSYA10-001 as a replication inhibitor of severe acute respiratory syndrome, mouse hepatitis, and Middle East respiratory syndrome coronaviruses, Antimicrob. Agents Chemother. 58 (2014), pp. 4894–4898. doi:10.1128/AAC.02994-14.
   PubMed Web of Science ®Google Scholar
• F. Ganzina, 4′-epi-doxorubicin, a new analogue of doxorubicin: A preliminary overview of preclinical and clinical data, Cancer. Treat. Rev. 10 (1983), pp. 1–22. doi:10.1016/S0305-7372(83)80029-2.
   PubMed Web of Science ®Google Scholar
• J.F. Borgio, H.S. Alsuwat, W.M. Al Otaibi, A.M. Ibrahim, N.B. Almandil, L.I. Al Asoom, M. Salahuddin, B. Kaaj, and S. AbdulAzeez, State-of-the-art tools unveil potent drug targets amongst clinically approved drugs to inhibit helicase in SARS-CoV-2, Arch. Med. Sci. 16 (2020), pp. 508–518. doi:10.5114/aoms.2020.94567.
   PubMed Web of Science ®Google Scholar
• S.L. Badshah, N. Ahmad, A. Ur Rehman, K. Khan, A. Ullah, A. Alsayari, A.B. Muhsinah, and Y. Mabkhot, Molecular docking and simulation of Zika virus NS3 helicase, BMC Chem. 13 (2019), pp. 67. doi:10.1186/s13065-019-0582-y.
   PubMed Web of Science ®Google Scholar
• A. Wadood, M. Riaz, R. Uddin, and Z. Ul-Haq, In silico identification and evaluation of leads for the simultaneous inhibition of protease and helicase activities of HCV NS3/4A protease using complex based pharmacophore mapping and virtual screening, PLoS One 9 (2014), pp. e89109. doi:10.1371/journal.pone.0089109.
   PubMed Web of Science ®Google Scholar
• P. Durai, M. Batool, M. Shah, and S. Choi, Middle East respiratory syndrome coronavirus: Transmission, virology and therapeutic targeting to aid in outbreak control, Exp. Mol. Med. 47 (2015), pp. e181. doi:10.1038/emm.2015.76.
   PubMed Web of Science ®Google Scholar
• L.D. Williams, C.A. Frederick, G. Ughetto, and A. Rich, Ternary interactions of spermine with DNA: 4′-epiadriamycin and other DNA: Anthracycline complexes, Nucleic Acids Res. 18 (1990), pp. 5533–5541. doi:10.1093/nar/18.18.5533.
   PubMed Web of Science ®Google Scholar
• E.R. Podell, D.J. Harrington, D.J. Taatjes, and T.H. Koch, Crystal structure of epidoxorubicin-formaldehyde virtual crosslink of DNA and evidence for its formation in human breast-cancer cells, Acta Crystallogr. D. Biol. Crystallogr. 55 (1999), pp. 1516–1523. doi:10.1107/s0907444999008161.
   PubMedGoogle Scholar
• J.P. Overington, B. Al-Lazikani, and A.L. Hopkins, How many drug targets are there, Nat. Rev. Drug Discov. 5 (2006), pp. 993–996. doi:10.1038/nrd2199.
   PubMed Web of Science ®Google Scholar
• P. Imming, C. Sinning, and A. Meyer, Drugs, their targets and the nature and number of drug targets, Nat. Rev. Drug Discov. 5 (2006), pp. 821–834. Erratum in: Nat. Rev. Drug Discov. 6 (2007) pp. 126. doi:10.1038/nrd2132.
   PubMed Web of Science ®Google Scholar
• T. Petit, M. Wilt, M. Velten, R. Millon, J.F. Rodier, C. Borel, R. Mors, P. Haegelé, M. Eber, and J.P. Ghnassia, Comparative value of tumour grade, hormonal receptors, Ki-67, HER-2 and topoisomerase II alpha status as predictive markers in breast cancer patients treated with neoadjuvant anthracycline-based chemotherapy, Eur. J. Cancer 40 (2004), pp. 205–211. doi:10.1016/s0959-8049(03)00675-0.
   PubMed Web of Science ®Google Scholar
• A.S. Knoop, H. Knudsen, E. Balslev, B.B. Rasmussen, J. Overgaard, K.V. Nielsen, A. Schonau, K. Gunnarsdóttir, K.E. Olsen, H. Mouridsen, and B. Ejlertsen, Retrospective analysis of topoisomerase IIa amplifications and deletions as predictive markers in primary breast cancer patients randomly assigned to cyclophosphamide, methotrexate, and fluorouracil or cyclophosphamide, epirubicin, and fluorouracil Danish Breast Cancer Cooperative Group, J. Clin. Oncol. 23 (2005), pp. 7483–7490. Erratum in: J. Clin. Oncol. 24 (2006), pp. 1015. doi:10.1200/JCO.2005.11.007.
   PubMed Web of Science ®Google Scholar
• C.H. Liang, L.Y. Shiu, L.C. Chang, H.M. Sheu, and K.W. Kuo, Solagine upregulation of Fas, downregulation of HER2, and enhancement of cytotoxicity using epirubicin in NSCLC cells, Mol. Nutr. Food Res. 51 (2007), pp. 999–1005. doi:10.1002/mnfr.200700044.
   PubMed Web of Science ®Google Scholar
• F.A. Fornari, J.K. Randolph, J.C. Yalowich, M.K. Ritke, and D.A. Gewirtz, Interference by doxorubicin with DNA unwinding in MCF-7 breast tumor cells, Mol. Pharmacol. 45 (1994), pp. 649–656.
   PubMed Web of Science ®Google Scholar
• R.L. Momparler, M. Karon, S.E. Siegel, and F. Avila, Effect of adriamycin on DNA, RNA, and protein synthesis in cell-free systems and intact cells, Cancer Res. 36 (1976), pp. 2891–2895.
   PubMed Web of Science ®Google Scholar
• C.A. Frederick, L.D. Williams, G. Ughetto, G.A. van der El, J.H. van Boom, A. Rich, and A.H. Wang, Structural comparison of anticancer drug-DNA complexes: Adriamycin and daunomycin, Biochemistry 29 (1990), pp. 2538–2549. doi:10.1021/bi00462a016.
   PubMed Web of Science ®Google Scholar
• X. Chen, Z.L. Ji, and Y.Z. Chen, TTD: Therapeutic target database, Nucleic Acids Res. 30 (2002), pp. 412–415. doi:10.1093/nar/30.1.412.
   PubMed Web of Science ®Google Scholar
• A. Rody, T. Karn, C. Solbach, R. Gaetje, M. Munnes, S. Kissler, E. Ruckhäberle, G.V. Minckwitz, S. Loibl, U. Holtrich, and M. Kaufmann, The erbB2+ cluster of the intrinsic gene set predicts tumor response of breast cancer patients receiving neoadjuvant chemotherapy with docetaxel, doxorubicin and cyclophosphamide within the GEPARTRIO trial, Breast 16 (2007), pp. 235–240. doi:10.1016/j.breast.2007.02.006.
   PubMed Web of Science ®Google Scholar
• H. Koehn, N. Magan, R.J. Isaacs, and K.M. Stowell, Differential regulation of DNA repair protein Rad51 in human tumour cell lines exposed to doxorubicin, Anticancer Drugs 18 (2007), pp. 419–425. doi:10.1097/CAD.0b013e328012a9a0.
   PubMed Web of Science ®Google Scholar
• G. Aubel-Sadron and D. Londos-Gagliardi, Daunorubicin and doxorubicin, anthracycline antibiotics, a physicochemical and biological review, Biochimie 66 (1984), pp. 333–352. doi:10.1016/0300-9084(84)90018-x.
   PubMed Web of Science ®Google Scholar
• F. Zunino and G. Canico, DNA topoisomerase II as the primary target of anti-tumor anthracyclines, Anticancer Drug Des. 5 (1990), pp. 307–317.
   PubMedGoogle Scholar
• Z. Hajihassan and A. Rabbani-Chadegani, Studies on the binding affinity of anticancer drug mitoxantrone to chromatin, DNA and histone proteins, J. Biomed. Sci. 16 (2009), pp. 31. doi:10.1186/1423-0127-16-31.
   PubMed Web of Science ®Google Scholar
• J. Mazerski, S. Telli, and E. Borowski, The geometry of intercalation complex of antitumor mitoxantrone and ametantrone with DNA: Molecular dynamics simulations, Acta. Biochim. Pol. 45 (1998), pp. 1–11.
   PubMed Web of Science ®Google Scholar
• K. Takeda, K. Shinohara, N. Kameda, and K. Ariyoshi, A case of therapy-related acute myeloblastic leukemia with t(16;21)(q24;q22) after chemotherapy with DNA-topoisomerase II inhibitors, etoposide and mitoxantrone, and the alkylating agent, cyclophosphamide, Int. J. Hematol. 67 (1998), pp. 179–186. doi:10.1016/s0925-5710(97)00108-4.
   PubMed Web of Science ®Google Scholar
• H. Wang, Y. Mao, N. Zhou, T. Hu, T.S. Hsieh, and L.F. Liu, ATP-bound topoisomerase II as a target for antitumor Drugs, J. Biol. Chem. 276 (2001), pp. 15990–15995. doi:10.1074/jbc.M011143200.
   PubMed Web of Science ®Google Scholar
• Z. Zahraei and A. Rabbani-Chadegani, A comparison of the effect of anticancer drugs, idarubicin and adriamycin, on soluble chromatin, Eur. J. Pharmacol. 575 (2007), pp. 28–33. doi:10.1016/j.ejphar.2007.07.045.
   PubMed Web of Science ®Google Scholar
• L.M. Hollingshead and D. Faulds, Idarubicin: A Review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the chemotherapy of cancer, Drugs 42 (1991), pp. 690–719. doi:10.2165/00003495-199142040-00010.
   PubMed Web of Science ®Google Scholar
• T. Fukushima, T. Ueda, M. Uchida, and T. Nakamura, Action mechanism of idarubicin (4-demethoxydaunorubicin) as compared with daunorubicin in leukemic cells, Int. J. Hematol. 57 (1993), pp. 121–130.
   PubMed Web of Science ®Google Scholar
• E. Willmore, F. Errington, M.J. Tilby, and C.A. Austin, Formation and longevity of idarubicin-induced DNA topoisomerase II cleavable complexes in K562 human leukaemia cells, Biochem. Pharmacol. 63 (2002), pp. 18007–18015. doi:10.1016/s0006-2952(02)00920-6.
   Web of Science ®Google Scholar
• R. Zhou, Y. Wang, A. Gruber, R. Larsson, E. Castaños-Vèlez, and E. Liliek, Topoisomerase II-mediated alterations of K562 drug resistant sublines, Med. Oncol. 16 (1999), pp. 191–198. doi:10.1007/BF02906131.
   PubMed Web of Science ®Google Scholar
• National Center for Biotechnology Information. PubChem compound summary for CID 72092, Otilonium Bromide, PubChem (2020). Available at https://pubchem.ncbi.nlm.nih.gov/compound/Otilonium-Bromide.
   Google Scholar
• A.J. Sucher, E.B. Chahine, and H.E. Balcer, Echinocandins: The newest class of antifungals, Ann. Pharmacother. 43 (2009), pp. 1647–1657. doi:10.1345/aph.1M237.
   PubMed Web of Science ®Google Scholar
• V.A. Morrison, Caspofungin: An overview, Expert Rev. Anti-Infect. Ther. 3 (2005), pp. 697–705. doi:10.1586/14787210.3.5.697.
   PubMedGoogle Scholar
• P.L. McCormack and C.M. Perry, Caspofungin: A review of its use in the treatment of fungal infections, Drugs 65 (2005), pp. 2049–2068. doi:10.2165/00003495-200565140-00009.
   PubMed Web of Science ®Google Scholar
• V. Ries, R. Selzer, T. Eichhorn, W.H. Oertel, K. Eggert, and G. Tolcapone, Replacing a dopamine agonist by the COMT-inhibitor tolcapone as an adjunct to L-dopa in the treatment of Parkinson’s disease: A randomized, multicenter, open-label, parallel-group study, Clin. Neuropharmacol. 33 (2010), pp. 142–150. doi:10.1016/j.bbrc.2007.02.156.
   PubMed Web of Science ®Google Scholar
• D.R. Guay, Tolcapone, a selective catechol-o-methyltransferase inhibitor for treatment of Parkinson’s disease, Pharmacotherapy 19 (1999), pp. 6–20. doi:10.1592/phco.19.1.6.30516.
   PubMed Web of Science ®Google Scholar
• T.J. Abrams, L.B. Lee, L.J. Murray, N.K. Pryer, and J.M. Cherrington, SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer, Mol. Cancer Ther. 2 (2003), pp. 471–478.
   PubMed Web of Science ®Google Scholar
• D.B. Mendel, A.D. Laird, X. Xin, S.G. Louie, J.G. Christensen, G. Li, R.E. Schreck, T.J. Abrams, T.J. Ngai, L.B. Lee, L.J. Murray, J. Carver, E. Chan, K.G. Moss, J.O. Haznedar, J. Sukbuntherng, R.A. Blake, L. Sun, C. Tang, T. Miller, S. Shirazian, G. McMahon, and J.M. Cherrington, In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: Determination of a pharmacokinetic/pharmacodynamics relationship, Clin. Cancer Res. 9 (2003), pp. 327–337.
   PubMed Web of Science ®Google Scholar
• A.M. O’Farrell, J.M. Foran, W. Fiedler, H. Serve, R.L. Paquette, M.A. Cooper, H.A. Yuen, S.G. Louie, H. Kim, S. Nicholas, M.C. Heinrich, W.E. Berdel, C. Bello, M. Jacobs, P. Scigalla, W.C. Manning, S. Kelsey, and J.M. Cherrington, An innovative phase I clinical study demonstrates inhibition of FLT3 phosphorylation by SU11248 in acute myeloid leukemia patients, Cancer Res. 9 (2003), pp. 5465–5476.
   Web of Science ®Google Scholar
• R. Roskoski, Sunitinib: A VEGF and PDGF receptor protein kinase and angiogenesis inhibitor, Biochem. Biophys. Res. Commun. 356 (2007), pp. 323–328. doi:10.1016/j.bbrc.2007.02.156.
   PubMed Web of Science ®Google Scholar
• S.E. Deprimo, C.L. Bello, J. Smeraglia, C.M. Baum, D. Spinella, B.I. Rini, M.D. Michaelson, and R.J. Motzer, Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: Modulation of VEGF and VEGF-related proteins, J. Transl. Med. 5 (2007), pp. 1–11. doi:10.1186/1479-5876-5-32.
   PubMed Web of Science ®Google Scholar
• J. Guo, P.A. Cotte, J.O. McCall, Y. Dai, L.J. Pease, M.R. Michaelides, S.K. Davidsen, and K.B. Glaser, Inhibition of phosphorylation of the colony-stimulating factor-1 receptor (c-Fms) tyrosine kinase in transfected cells by ABT-869 and other tyrosine kinase inhibitors, Mol. Cancer Ther. 5 (2006), pp. 1007–1013. doi:10.1158/1535-7163.MCT-05-0359.
   PubMed Web of Science ®Google Scholar
• H. Prenen, J. Cools, N. Mentens, C. Folens, R. Sciot, P. Schöffski, A. Van Oosterom, P. Ynen, and M. Debiec-Rychter, Efficacy of the kinase inhibitor SU11248 against gastrointestinal stromal tumor mutants refractory to imatinib mesylate, Clin. Cancer Res. 12 (2006), pp. 2622–2627. doi:10.1517/14656566.2013.783019.
   PubMed Web of Science ®Google Scholar
• K. Kobayashi, S. Yamagami, T. Higuchi, M. Hosokawa, and K. Chiba, Key structural features of ligands for activation of human pregnane X receptor, Drug Metab. Dispos. 32 (2004), pp. 468–472. doi:10.1124/dmd.32.4.468.
   PubMed Web of Science ®Google Scholar
• C. Gruber and D. Gruber, Bazedoxifene (Wyeth), Curr. Opin. Investig. Drugs 5 (2004), pp. 1086–1093.
   PubMedGoogle Scholar
• B.S. Komm, Y.P. Kharode, P.V.N. Bodine, H.A. Harris, C.P. Miller, and C.R. Lyttle, Bazedoxifene acetate: A selective estrogen receptor modulator with improved selectivity, Endocrinology 146 (2005), pp. 3999–4008. doi:10.1210/en.2005-0030.
   PubMed Web of Science ®Google Scholar
• National Center for Biotechnology Information. PubChem Compound Summary for CID 10074640, Masitinib, PubChem (2020). Available at https://pubchem.ncbi.nlm.nih.gov/compound/Masitinib.
   Google Scholar
• F. Cervantes and A. Tinez-Trillos, Myelofibrosis: An update on current pharmacotherapy and future directions, Expert Opin. Pharmacother. 14 (2013), pp. 873–884. doi:10.1517/14656566.2013.783019.
   PubMed Web of Science ®Google Scholar
• L.P.H. Yang and G.M. Keating, Ruxolitinib: In the treatment of myelofibrosis, Drugs 72 (2012), pp. 2117–2127. doi:10.2165/11209340-000000000-00000.
   PubMed Web of Science ®Google Scholar
• H.U. Bryant, A.L. Glasebrook, N.N. Yang, and M. Sato, An estrogen receptor basis for raloxifene action in bone, J. Steroid Biochem. Mol. Biol. 69 (1999), pp. 37–44. doi:10.1016/s0960-0760(98)00147-2.
   PubMed Web of Science ®Google Scholar
• A.J. Krieg, S.A. Krieg, B.S. Ahn, and D.J. Shapiro, Interplay between estrogen response element sequence and ligands controls in vivo binding of estrogen receptor to regulated genes, J. Biol. Chem. 279 (2004), pp. 5025–5034. doi:10.1074/jbc.M307076200.
   PubMed Web of Science ®Google Scholar
• H.M. Berman, J. Westbrook, Z. Feng, G. Gilliland, T.N. Bhat, H. Weissig, I.N. Shindyalov, and P.E. Bourne, The protein data bank, Nucleic Acids Res. 28 (2000), pp. 235–242. doi:10.1093/nar/28.1.235.
   PubMed Web of Science ®Google Scholar
• W.R. Shadrick, J. Ndjomou, R. Kolli, S. Mukherjee, A.M. Hanson, and D.N. Frick, Discovering new medicines targeting helicases: Challenges and recent progress, J. Biomol. Screen. 18 (2013), pp. 761–781. doi:10.1177/1087057113482586.
   PubMed Web of Science ®Google Scholar
• S. Charak, D.K. Gir, G. Tyagi, and R. Mehrotra, Interaction studies of epirubicin with DNA using spectroscopic techniques, J. Mol. Struct. 1000 (2011), pp. 150–154. doi:10.1016/j.molstruc.2011.06.013.
   Web of Science ®Google Scholar
• S.R. Byrn and G.D. Dolch, Analysis of binding of daunorubicin and doxorubicin to DNA using computerized curve‐fitting procedures, J. Pharm. Sci. 67 (1978), pp. 688–693. doi:10.1002/jps.2600670532.
   PubMed Web of Science ®Google Scholar
• C. Ozluer and H.E.S. Kara, In vitro DNA binding studies of anticancer drug idarubicin using spectroscopic techniques, J. Photochem. Photobiol. B 138 (2014), pp. 36–42. doi:10.1016/j.jphotobiol.2014.05.015.
   PubMed Web of Science ®Google Scholar